Eli Lilly and Co (LLY, Financial) announced its financial results for the fourth quarter of 2024, reporting a 45% increase in revenue to $13.53 billion, driven by strong performance from key products Mounjaro and Zepbound. The company also highlighted significant pipeline progress, including U.S. approvals for Zepbound and Omvoh, and announced a pending acquisition of Scorpion Therapeutics' PI3Kα inhibitor program. The press release, dated February 6, 2025, also provided guidance for 2025, projecting revenue between $58.0 billion and $61.0 billion and EPS between $22.05 and $23.55.
Positive Highlights
- Q4 2024 revenue increased by 45% to $13.53 billion.
- EPS increased by 102% to $4.88 on a reported basis.
- Significant pipeline progress with approvals for Zepbound and Omvoh in the U.S.
- Pending acquisition of Scorpion Therapeutics' PI3Kα inhibitor program.
- 2025 revenue guidance set between $58.0 billion and $61.0 billion.
Negative Highlights
- Lower realized prices partially offset revenue growth.
- Increased marketing, selling, and administrative expenses by 26%.
- Asset impairment, restructuring, and other special charges increased to $344.0 million.
Financial Analyst Perspective
From a financial analyst's perspective, Eli Lilly's Q4 2024 results demonstrate robust growth, driven by strategic product launches and pipeline advancements. The significant increase in EPS and revenue reflects the company's effective execution of its growth strategy. However, the rise in marketing and administrative expenses indicates increased investment in product promotion, which could impact short-term profitability. The 2025 guidance suggests continued strong performance, supported by new product launches and market expansions.
Market Research Analyst Perspective
As a market research analyst, Eli Lilly's performance in Q4 2024 highlights its competitive positioning in the pharmaceutical industry. The approval of new treatments for obstructive sleep apnea and Crohn's disease, along with the acquisition of Scorpion Therapeutics' program, underscores the company's commitment to expanding its therapeutic offerings. The projected revenue growth for 2025 suggests a positive market reception for its new and existing products, positioning Eli Lilly for sustained market leadership.
Frequently Asked Questions
What was Eli Lilly's revenue for Q4 2024?
$13.53 billion, a 45% increase from Q4 2023.
What is the EPS for Q4 2024?
$4.88 on a reported basis, a 102% increase.
What are the key product approvals mentioned?
Zepbound for obstructive sleep apnea and Omvoh for Crohn's disease in the U.S.
What is the 2025 revenue guidance?
Between $58.0 billion and $61.0 billion.
What strategic acquisition did Eli Lilly announce?
The pending acquisition of Scorpion Therapeutics' PI3Kα inhibitor program.
Read the original press release here.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
